Oncopeptides AB (publ)

Stockholm Stock Exchange ONCO.ST

Oncopeptides AB (publ) Shareholders' Equity for the year ending December 31, 2023: USD 5.60 M

Oncopeptides AB (publ) Shareholders' Equity is USD 5.60 M for the year ending December 31, 2023, a -80.06% change year over year. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.

Oncopeptides AB (publ) Shareholders' Equity for the year ending December 31, 2022 was USD 28.10 M, a 21.06% change year over year.
Oncopeptides AB (publ) Shareholders' Equity for the year ending December 31, 2021 was USD 23.22 M, a -66.80% change year over year.
Oncopeptides AB (publ) Shareholders' Equity for the year ending December 31, 2020 was USD 69.92 M, a -17.55% change year over year.
Oncopeptides AB (publ) Shareholders' Equity for the year ending December 31, 2019 was USD 84.80 M.

Key data

Date	Shareholders' Equity	Minority Interest	Total Equity	Total Stockholders Equity and Liabilities

Stockholm Stock Exchange: ONCO.ST

Oncopeptides AB (publ)

CEO	Ms. Sofia Heigis M.Sc.
IPO Date	Feb. 22, 2017
Location	Sweden
Headquarters	Vastra Tradgardsgatan 15
Employees	79
Sector	Healthcare
Industries Biotechnology Pharmaceuticals Plastics

Description

Oncopeptides AB (publ), a biotech company, develops pharmaceuticals drugs for the treatment of cancer in the United States, Europe, and internationally. Its lead product candidate is melflufen, an anti-cancer peptide drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden.

Key trends

Past 5 years